<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252131</url>
  </required_header>
  <id_info>
    <org_study_id>106-046</org_study_id>
    <nct_id>NCT04252131</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia</brief_title>
  <official_title>Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calo Psychiatric Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calo Psychiatric Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia patients with anti-psychotics have decreased psychiatric symptoms, but have
      increased the generation of overweight or obesity. There is correlation between obesity,
      diabetes mellitus, metabolic syndrome, hypertension, hyperlipidemia and cardiovascular
      disorders. Cassia seed is one of traditional Chinese herbs, that can decline blood lipedema
      effect. Therefore, the purpose of the present study was to design a randomized, double blind,
      control group study to assess the therapeutic effect of Cassia seed in schizophrenia patients
      with obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total of 92 schizophrenia patients with obesity will be enrolled and divided randomly into:
      1) case group, received oral administration of Cassia seed (3.0g), once/day, 12 weeks; 2)
      control group, received oral administration of Cassia seed placebo (3.0g), once/day (90% of
      starch and 10% of cassia obtusifolia), 12 weeks. The primary outcome included the changes of
      body mass index (BMI), waist circumferences (WC); secondary outcome measured included the
      changes of hemoglobin A1c (HbA1c), total cholesterol, triglyceride, high density lipoprotein,
      low density lipoprotein, CRP (C-Reactive protein), IL-6, systolic blood pressure, diastolic
      blood pressure, and meridian energy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Total of 92 schizophrenia patients with obesity was divided randomly into: 1) control group, received oral administration of Cassia seed placebo (3.0g), once/day for 12 weeks continuously; 2) treatment group, received oral administration of Cassia seed (3.0g), once/day for 12 weeks continuously.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All participants are randomized into treatment or placebo group. Investigator also did not know who are in which group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>physiological parameter for measuring Height and weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>the parameter of BMI in kg/m^2 for exploring the changes of body mass index (BMI) after cassia obtusifolia treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sphygmomanometer</measure>
    <time_frame>12 weeks</time_frame>
    <description>the parameter of systolic blood pressure and diastolic blood pressure after cassia obtusifolia treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood analyzer</measure>
    <time_frame>12 weeks</time_frame>
    <description>the concentration of lipid profile, including total cholesterol, triglyceride, high denisty lipoprotein and low density lipoprotein after cassia obtusifolia treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meridian energy skin conductivity assessment using amperometer (0-200uA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>the parameter of meridian energy after cassia obtusifolia treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cassia seed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of Cassia seed (3.0g), once/day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cassia seed placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cassia seed tablet</intervention_name>
    <description>traditional Chinese herbs</description>
    <arm_group_label>Cassia seed</arm_group_label>
    <arm_group_label>Cassia seed placebo</arm_group_label>
    <other_name>cassia obtusifolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 65 years

          -  diagnosed as schizophrenia at least more 6 months

          -  no major systemic illnesses based on physical examinations and laboratory test results

          -  BMI &gt;= 24, WC &gt;= 80 cm in female, WC &gt;= 90 cm in male

        Exclusion Criteria:

          -  participants were pregnant and lactating women

          -  allergy to Cassia

          -  SGOT or SGPT more than 2 times normal level

          -  BUN or creatinine more than normal level

          -  Fasting blood glucose (serum) &gt; 140 mg/dL, systolic blood pressure &gt; 180 mmHg,
             diastolic blood pressure &gt; 110 mmHg, serum triglyceride &gt; 400 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>For-Wey Lung, MD, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Calo Psychiatric Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Calo Psychiatric Center</name>
      <address>
        <city>Pingtung</city>
        <state>Others</state>
        <zip>925</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 26, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Calo Psychiatric Center</investigator_affiliation>
    <investigator_full_name>For-Wey Lung</investigator_full_name>
    <investigator_title>superintendent</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Cassia seed</keyword>
  <keyword>obesity</keyword>
  <keyword>Therapeutic effect assessment</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

